1/20/2024 0 Comments Sentinel lymph node biopsy neckIl SN non è stato identificato in 26 pazienti. In questo studio prospettico, dal maggio 1999 al dicembre 2009, sono stati analizzati 209 pazienti consecutivi: 61,7% con tumore primitivo della cavità orale e 23,9% dell'orofaringe. La biopsia del linfonodo sentinella (SN) nel carcinoma squamocellulare della testa e collo è ancora considerata investigazionale e non è stata raggiunta unanimità su quanto ampio debba essere il prelievo da utilizzare. Outside the framework of a clinical study, the best treatment can still be considered SND. The minimum treatment of the neck is probably dissection of the levels between the primary tumour and the level containing the SN(s). SN biopsy can be considered a useful tool to personalize the surgical approach to a N0 carcinoma. Considering the six hypothetic scenarios: "only SN removal", "SN level dissection", "neck dissection from the tumour site to SN level", "selective neck dissection of three levels (SND)", "dissection from level I to IV" and "comprehensive I-V dissection", neck recurrences could be expected in 6.5%, 3.8%, 2.18%, 2.73%, 1.09% and 1.09% of cases, respectively. Based on these data and definitive histopathological analysis, we proposed six hypothetic scenarios to understand the percentage of neck recurrences following different treatments Among patients with identified SN, 54 cases were pN+: 47 in SN and 7 in a different node. From May 1999 to Dec 2009, 209 consecutive patients entered a prospective study: 61.7% had primary tumour of the oral cavity and 23.9% of the oropharynx. Sentinel node (SN) biopsy of head and neck cancer is still considered investigational, and agreement on the width of the surgical sampling has not yet been reached.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |